Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4638146 | 0.98 | LMNA (0.33) | LMNAHTTALDH1A1MAPTKDM4E | |
| SCHEMBL852975 | 0.82 | POLB (0.40) | LMNAHTTALDH1A1MAPTKDM4E | |
| SCHEMBL14182015 | 0.82 | NPSR1 (0.38) | LMNAHTTALDH1A1MAPTKDM4E | |
| SCHEMBL3217738 | 0.81 | MAPT (0.42) | LMNAHTTALDH1A1MAPTKDM4E | |
| SCHEMBL1441268 | 0.81 | KCNH3 (0.41) | LMNAALDH1A1MAPT | |
| SCHEMBL6177680 | 0.79 | KCNH3 (0.42) | LMNAHTTALDH1A1MAPTKDM4E | |
| SCHEMBL6951347 | 0.78 | CA12 (0.38) | LMNAHTTALDH1A1KDM4ETDP1 | |
| SCHEMBL6860751 | 0.77 | SLC2A1 (0.47) | LMNAHTTALDH1A1MAPTKDM4E | |
| Bromide SCHEMBL7169789 | 0.73 | — | — | |
| SCHEMBL7711293 | 0.72 | SLC2A1 (0.49) | LMNAALDH1A1MAPTKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1628949-A4 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORP (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7368566-B2 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368566-B2 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20060194786-A1 | Process and intermediates for preparing benzazepines | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| EP-1628949-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-01 | — | — | EP | disclosed |
| EP-1061921-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004089890-A2 | PROCESS AND INTERMEDIATES FOR PREPARING BENZAZEPINES | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| EP-1061921-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-27 | — | — | EP | disclosed |
| WO-1999045927-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194786-A1 | Process and intermediates for preparing benzazepines | CYP2E1, CYP1B1, CYP3A4 | LMNA 692/4885HTT 3368/4885ALDH1A1 279/4885 |
| US-20020147334-A1 | Vitronectin Receptor Antagonists | ADGRF1, FN1, CALCR | LMNA 346/4885HTT 4663/4885ALDH1A1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.